Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer
Liqiu Liao, Mei Song, Xin Li, et al.
Cancer Research (2017) Vol. 77, Iss. 8, pp. 2090-2101
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges
Mohammad Ahmed Khan, Vineet Jain, Md. Rizwanullah, et al.
Drug Discovery Today (2019) Vol. 24, Iss. 11, pp. 2181-2191
Closed Access | Times Cited: 203
Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer
Huimin Zhang, Chunhong Qin, Changming An, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 169
Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint
Navin Kumar Verma, Brandon Han Siang Wong, Zhi Sheng Poh, et al.
EBioMedicine (2022) Vol. 83, pp. 104216-104216
Open Access | Times Cited: 81
The ubiquitin–proteasome system in breast cancer
Dianwen Han, Lijuan Wang, Shan Jiang, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 8, pp. 599-621
Closed Access | Times Cited: 44
SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1
Ling Deng, Li Liao, Yin‐Ling Zhang, et al.
Science Advances (2024) Vol. 10, Iss. 14
Open Access | Times Cited: 20
Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages
Mei Song, Oladapo O. Yeku, Sarwish Rafiq, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 120
HECT E3 ubiquitin ligases – emerging insights into their biological roles and disease relevance
Yaya Wang, Diana Argiles-Castillo, Emma I. Kane, et al.
Journal of Cell Science (2020) Vol. 133, Iss. 7
Open Access | Times Cited: 112
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Hua A Han, Jeremy Kah Sheng Pang, Boon-Seng Soh
Journal of Molecular Medicine (2020) Vol. 98, Iss. 5, pp. 615-632
Open Access | Times Cited: 93
UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer
Bingbing Wu, Mei Song, Qun Dong, et al.
Theranostics (2022) Vol. 12, Iss. 11, pp. 5086-5102
Open Access | Times Cited: 56
CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope
Vamika Karn, Sandhya Sandhya, Wayne Hsu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 46
Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
Isidro Cortés‐Ciriano, Christopher D. Steele, Katherine Piculell, et al.
Cancer Discovery (2023) Vol. 13, Iss. 3, pp. 654-671
Open Access | Times Cited: 41
Orphan quality control shapes network dynamics and gene expression
Kevin G. Mark, SriDurgaDevi Kolla, Jacob D. Aguirre, et al.
Cell (2023) Vol. 186, Iss. 16, pp. 3460-3475.e23
Open Access | Times Cited: 36
Structural snapshots along K48-linked ubiquitin chain formation by the HECT E3 UBR5
Laura A. Hehl, Daniel Horn‐Ghetko, J. Rajan Prabu, et al.
Nature Chemical Biology (2023) Vol. 20, Iss. 2, pp. 190-200
Open Access | Times Cited: 36
Structure of the human UBR5 E3 ubiquitin ligase
Feng Wang, Qing He, Wenhu Zhan, et al.
Structure (2023) Vol. 31, Iss. 5, pp. 541-552.e4
Open Access | Times Cited: 28
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
Bo Hou, Ting Chen, He Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Cryo‐EM structure of the chain‐elongating E3 ubiquitin ligase UBR5
Zuzana Hodáková, Irina Grishkovskaya, Hanna L. Brunner, et al.
The EMBO Journal (2023) Vol. 42, Iss. 16
Open Access | Times Cited: 23
CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
Bin Liu, Ali Saber, Hidde J. Haisma
Drug Discovery Today (2019) Vol. 24, Iss. 4, pp. 955-970
Open Access | Times Cited: 64
Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment
Chunyang Jiang, Lingxiang Meng, Bingjun Yang, et al.
Clinical Genetics (2019) Vol. 97, Iss. 1, pp. 73-88
Closed Access | Times Cited: 57
E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα
Leifeng Chen, Rongfa Yuan, Chongyu Wen, et al.
Oncogene (2020) Vol. 40, Iss. 2, pp. 262-276
Closed Access | Times Cited: 57
Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models
Yisheng Huang, Zhijie Huang, Zhengming Tang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 55
CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics
Prashant Kumar Tiwari, Tin-Hsien Ko, Rajni Dubey, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 20
Advances in breast cancer research using CRISPR/Cas9 system
Fatemeh Eskandari, Mahdi Aali, Seyedeh Negin Hadisadegh, et al.
Nano Select (2024) Vol. 5, Iss. 10
Closed Access | Times Cited: 7
UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis
Xi Qiao, Ying Liu, Maria Llamazares Prada, et al.
Cancer Research (2020) Vol. 80, Iss. 7, pp. 1414-1427
Open Access | Times Cited: 47
UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer
Gang Xiang, Shuxuan Wang, Ling Chen, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 24
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Xian-Miao Li, Zhenyu Zhao, Yu Xiao, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top